nivolumab

  • July 28, 2021  

    2021 ASCO Annual Meeting Bookmark

    George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  • July 14, 2021  

    What’s New in Melanoma Treatment in 2021?

    Emma Shtivelman, PhD

    I last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Immune checkpoint inhibitors (ICI), antibody drugs that bind to proteins found on the immune system’s T cells—namely, PD-1 (which is targeted by the… Read more »

  • April 12, 2021  

    Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer Bookmark

    George Lundberg, MD

    The ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.

    .

  • April 12, 2021  

    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Bookmark

    George Lundberg, MD

    An academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.

    .

  • December 3, 2020  

    Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer Bookmark

    George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .

  • November 24, 2020  

    For Esophageal Cancer, Immunotherapy Likely to Play Larger Role Bookmark

    George Lundberg, MD

    A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

    .

  • November 24, 2020  

    Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Bookmark

    George Lundberg, MD

    This scientific research paper published in JAMA Oncology reports results from a clinical trial in which the drugs nivolumab and ipilimumab showed promising safety and efficacy for people with advanced liver cancer who had previously received the drug sorafenib.

    .

  • August 15, 2020  

    ICI for Resected Stage IV Melanoma Bookmark

    George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial for metastatic melanoma patients, a combination of the drugs nivolumab and ipilimumab (both “immune checkpoint inhibitors,” or ICIs) outperformed nivolumab on its own, and nivolumab on its own outperformed a placebo.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Bookmark

    George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.